
Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 3 December 2020Portfolio NewsMerck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
- 23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors
- 23 November 2020Portfolio NewsThe Boston Globe Names Deciphera a Top Place to Work for 2020
- 18 November 2020Portfolio NewsPionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314
- 18 November 2020Portfolio NewsSutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
- 17 November 2020Portfolio NewsAVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline
- 10 November 2020Portfolio NewsXilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- 10 November 2020SV NewsKate Bingham writes the foreword for Movers and Shakers in BioBusiness 2020
- 29 September 2020Portfolio NewsAlchemab partners with Amii to accelerate the development of novel therapeutics to cure disease
- 28 September 2020Portfolio NewsAVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
- 18 September 2020SV NewsSV Health Investors welcomes six new Venture Partners to the Biotech team
- 15 September 2020Portfolio NewsSV Health Investors announces launch of biotech portfolio company, Cellinta and the Company’s appointment of Dr Soraya Bekkali as CEO